Heterozygous α1 antitrypsin (α1-AT) phenotypes have been suggested to contribute to the risk of developing asthma and atopic diseases in children and adults. Lack of an effective airway protease screen may contribute to the inflammatory processes characteristic of asthma in predisposed children, which may lead to an increased risk for the development of asthma, reduced pulmonary function, and signs of more severe symptoms of asthma and related atopic disorders.

The relation between the prevalence and severity of asthma and allergic disorders and Pi heterozygosity and α1-AT plasma levels, respectively, was studied in two large random samples of school children in eastern and western Germany.

METHODS

Using the ISAAC phase II study protocol, cross-sectional surveys addressing all fourth graders (aged 9–11 years) via parental questionnaires (including the ISAAC core questions) at randomly selected schools in Dresden (n = 3668) and Munich (n = 3830), Germany, were performed in 1995 and 1996; results are described in detail elsewhere. A child with a reported doctor’s diagnosis of asthma or recurrent asthmatic or spastic bronchitis was classified as having asthma. Among asthmatics, the frequencies of asthmatic symptoms and episodes, medication, and hospital admissions were assessed.

Plasma α1-AT concentrations were measured using the rate nephelometric immunochemistry system (ICS, Arrayly, Beckman Instruments, Fullerton, CA, USA). Genotyping of α1-AT deficiency alleles PiZ and PiS was done using polymerase chain reaction techniques. Plasma specimens not typing for PiZ or PiM were defined as having other Pi genotypes.

As the lung function measurements and the bronchial challenge were time consuming, they were offered only to a random subsample of children in Dresden (n = 1999) and Munich (n = 2019). Bronchial hyperreactivity (BHR) was assessed as a fall in FEV1 of at least 15% after challenge with a 4.5% hyperosmolar saline solution. Atopy assessment and lung function measurement is described in detail elsewhere.

Statistical analysis

The analysis was restricted to children with German nationality, which reflects ethnicity rather than place of birth in Germany. Wilcoxon tests, t tests, and χ2 tests were computed for bivariate comparisons. The cut-off limit for low levels of α1-AT was defined as the 5th centile (≤ 116 mg/dl) of the population distribution. Baseline pulmonary function values were computed as percent predicted standardised for age, height, and weight separately for girls and boys.

RESULTS

The participation rates of the two study centres are reported in detail elsewhere. Overall, 6399 parents of the 7498 addressed children completed the questionnaire (85.3%). 5629 of the participants were of German origin (87.8%) (median age 10 years, range 9–13 years). Both lung function measurements and blood samples were obtained for 48.8% of the eligible German children.

Prevalence rates for symptoms and diagnoses of asthma, allergic and respiratory disorders, or a family history of asthma or hay fever were not significantly associated with Pi genotype, or average plasma levels of α1-AT. The asthma prevalence was 4.9% (n = 4) for PiMZ, 6.5% (n = 8) for PiMS, and 9.2% (n = 279) for other genotypes. Only the prevalence of BHR was increased among subjects with PiMZ (27.8%, 10/36) versus PiMS (19.6%, 11/56) and other genotypes (16.9%, 227/1346), being in line with the increased prevalence of BHR among children with low levels of α1-AT (≤ 116 mg/dl) in comparison to children with normal α1-AT values (23.1%, 12/52 v 16.9%, 234/1382) in the total sample. However, these differences did not reach statistical significance, which may be due to the small numbers in subgroups.

No consistent association between plasma levels of α1-AT and atopic sensitisation was observed.

Among children with asthma or BHR, low levels of α1-AT were related to significant decrements in FEV1 and MEF50 (table 1). Asthmatics with PiMZ genotype showed similar, though non-significant, reductions in lung function compared to PiMS or other genotypes (median levels of % predicted (SE): MEF75: 85.9 (19.9) v 101.2 (16.4) v 94.5 (18.2); MEF50: 84.5 (35.1) v 99.0 (12.9) v 91.8 (23.2)).

The severity of asthma, assessed as the frequency of symptoms, hospital admissions, days missing from school, and asthma medication intake, was not affected by low α1-AT plasma levels. Only BHR was increased among asthmatic children with low levels of α1-AT compared to asthmatics with normal levels (60%, 234/385 v 35%, 43/123). However, the difference did not reach statistical significance, probably because of the small numbers in the subgroups.

DISCUSSION

The findings of this study suggest that the risk of developing asthma or hay fever is not increased in children with α1-AT Pi heterozygosity or low α1-AT plasma concentrations. Low levels of α1-AT were related to impaired lung function among children with asthma; however, the number of children in the subgroups was relatively small (table 1). The observed
relation to BHR may be spurious because of small numbers in the various categories. The association between atopy and low $\alpha_1$-AT was inconsistent.

Neutrophil elastase has been shown to be involved in bronchoconstriction and airway hyperresponsiveness, and the disruption of the elastic fibre network of the lung, thereby reducing elastic recoil. Thus, an imbalance of the elastase/$\alpha_1$-AT levels in the lung may indeed contribute to airway inflammation and thereby to increased airway responsiveness and impaired lung function among asthmatic children. Findings among adults reporting an increased risk for BHR in subjects with both heterozygous genotypes and reduced $\alpha_1$-AT levels further support this notion.

In conclusion, this study proposes that heterozygous Pi genotypes or low levels of $\alpha_1$-AT in plasma do not enhance the risk of children developing asthma or hay fever. The findings suggest, however, that an impaired $\alpha_1$-AT balance may potentially increase the vulnerability for decrements in lung function and BHR in children who already have asthma, which needs to be confirmed or rejected by further investigations.

ACKNOWLEDGEMENTS
This work was supported by the Bundesministerium für Bildung, Forschung und Technologie (German Ministry for the Sciences and Technology) and the Centre for Environment and Health (Project Environment and Health, Baden-Württemberg).

We thank the Laboratory Becker, Olgemöller & Partner, Munich, for genotyping the PiZ allele.

Authors’ affiliations
O S von Ehrenstein, E M Maier, D Carr, T Nicolai, A A Roscher, E von Mutius, University Children’s Hospital, Munich, Germany
S K Weiland, University of Münster, Institute of Epidemiology and Social Medicine, Germany
T Hirsch, Children’s Hospital, Technical University, Dresden, Germany

Correspondence to: Dr E von Mutius, Dr von Haunersche Kinderklinik, Lindwurmstr. 4, D-80337 München, Germany; Erika.Von.Mutius@med.uni-muenchen.de

Accepted 25 June 2003

REFERENCES
1 Lindmark B, Svenonius E, Eriksson S. Heterozygous $\alpha_1$-antichymotrypsin and $\alpha_1$-antitrypsin deficiency. Allergy 1990;45:197–203.

Table 1 Pulmonary function† in children with asthma or BHR according to presence or absence of low plasma level of $\alpha_1$-AT (≤ 116 mg/dl)

<table>
<thead>
<tr>
<th>$\alpha_1$-AT ≤ 116 (n = 16)‡</th>
<th>$\alpha_1$-AT &gt; 116 (n = 341)‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>FVC 95.5 (3.0)</td>
<td>100.3 (0.6)</td>
</tr>
<tr>
<td>FEV1 92.6 (2.9)*</td>
<td>98.2 (0.6)</td>
</tr>
<tr>
<td>FEV1/FVC 97.0 (1.3)</td>
<td>98.2 (0.4)</td>
</tr>
<tr>
<td>PEF 88.4 (4.2)</td>
<td>97.1 (1.0)</td>
</tr>
<tr>
<td>MEF25 87.5 (4.1)</td>
<td>94.6 (1.0)</td>
</tr>
<tr>
<td>MEF50 79.5 (6.8)*</td>
<td>92.1 (1.2)</td>
</tr>
<tr>
<td>MEF75 82.3 (6.2)</td>
<td>92.1 (1.8)</td>
</tr>
<tr>
<td>MMEF 82.9 (4.7)</td>
<td>92.0 (1.3)</td>
</tr>
</tbody>
</table>

† Pulmonary function adjusted for height, weight, and gender.
‡ P < 0.05; † test in comparison to children with asthma or BHR and $\alpha_1$-AT > 116 mg/dl.

Pulmonary function adjusted for height, weight, and gender. Least square mean (SE).